Cross Labeling Oncology Drugs in Combination Drug Regimens; Draft Guidance for Industry; Availability

摘要

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Cross Labeling Oncology Drugs in Combination Drug Regimens." This guidance describes FDA's current recommendations on including relevant information in labeling for oncology drugs approved for use in combination drug regimens.